Physician profile
Jacobo Pena
NPI 1467688622
$1,128.04
in general payments reported to CMS, 2019-2025
16 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.74 · 2020: $167 · 2021: $259 · 2022: $57.50 · 2023: $326 · 2024: $159 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $432.02 | 2021-2025 | |
| Astellas Pharma US INC | $209.66 | 2020-2023 | Veozah, Myrbetriq |
| Novo Nordisk INC | $74.33 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $58.19 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $53.71 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.74 | 2019 | |
| Merck Sharp & Dohme LLC | $43.18 | 2020-2021 | |
| Lilly USA, LLC | $42.53 | 2023-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $39.76 | 2020-2021 | |
| Eisai INC. | $23.89 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.22 | 2022 | |
| Amgen INC. | $22.94 | 2021 | |
| Exact Sciences Corporation | $15.70 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $15.11 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.47 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacobo Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.